IP Library › Patent Application 11058981
Patent Application
App. No. 11/058,981

Method for treating obesity

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/058,981
Abstract

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims (18)

1 - 17 . (canceled)

18 . A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one weight-loss promoting anticonvulsant selected from the group consisting of zonisamide and topiramate, and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said treatment is effected.

19 . The method of claim 18 wherein said anticonvulsant is zonisamide.

20 . The method of claim 18 wherein said compound that enhances the activity of norepinephrine and/or dopamine is selected from the group consisting of bupropion, atomoxetine, and reboxetine.

21 . The method of claim 18 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.

22 . The method of claim 18 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.

23 . The method of claim 18 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.

24 . A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such treatment at least one weight-loss promoting anticonvulsant selected from the group consisting of zonisamide and topiramate, and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said reduction is effected.

25 . The method of claim 24 wherein said anticonvulsant is zonisamide.

26 . The method of claim 24 wherein said compound that enhances the activity of norepinephrine and/or dopamine is selected from the group consisting of bupropion, atomoxetine, and reboxetine.

27 . The method of claim 24 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.

28 . A composition comprising at least one weight-loss promoting anticonvulsant selected from the group consisting of zonisamide and topiramate, and at least one compound that enhances the activity of norepinephrine and/or dopamine.

29 . The composition of claim 24 wherein said anticonvulsant is zonisamide.

30 . The composition of claim 24 wherein said compound that enhances the activity of norepinephrine and/or dopamine is selected from the group consisting of bupropion, atomoxetine, and reboxetine.

31 . The composition of claim 24 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.

32 . The composition of claim 24 wherein said compound is in dosage unit form.

33 . The composition of claim 24 wherein said composition is in the form of a tablet or capsule.

34 . The composition of claim 24 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion and said anticonvulsant is zonisamide.